Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 19

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 19
---
 audit
firms based in mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered
public accounting firms headquartered in mainland China and Hong Kong. Pursuant to the fact sheet with respect to the Protocol disclosed
by the SEC, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and has the unfettered
ability to transfer information to the SEC. On December 15, 2022, the PCAOB Board determined that the PCAOB was able to secure complete
access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and voted to vacate
its previous determinations to the contrary. However, should PRC authorities obstruct or otherwise fail to facilitate the PCAOB’s
access in the future, the PCAOB Board will consider the need to issue a new determination.

The Company now focuses all
of its efforts on R&D; it no longer performs any therapeutic services. While the Company may commence therapeutic services in the
future, as of December 31, 2024 and the date hereof, it only operates in one segment.

<div align='center'>3</div>

Recent Events

Registered Direct Offering and Concurrent Private Placement

On October 10, 2025, the Company
entered into certain securities purchase agreement (the “Purchase Agreement”) with certain non-affiliated institutional
investors (the “Purchasers”) pursuant to which the Company agreed to sell (1) 1,000,000 Class A Ordinary Shares pursuant
to an effective registration statement, and (2) in a concurrent private placement, unregistered warrants to purchase an aggregate of up
to 2,000,000 Ordinary Shares (the “October 2025 Warrants”), for aggregate gross proceeds of approximately $2 million
(the “October 2025 Offering”).

Each October 2025 Warrant
is exercisable immediately as of the date of issuance at an exercise price of $2.00 per Ordinary Share and expires twenty-four months
from the effective date of this registration statement. The October 2025 Warrants and the Ordinary Shares issuable upon the exercise of
the warrants were not registered under the Securities Act of 1933, as amended (the “Securities Act”) and were offered
pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or
Rule 506(b) of Regulation D.

The Company agreed